Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3.

@article{Chvatchko2003InhibitionOA,
  title={Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3.},
  author={Yolande Chvatchko and Amanda E. I. Proudfoot and Rapha{\"e}le Buser and Pierre Juillard and Sami Alouani and Marie H. Kosco-Vilbois and Anthony J Coyle and Robert J B Nibbs and Gerard J Graham and Robin E. Offord and Timothy N. C. Wells},
  journal={Journal of immunology},
  year={2003},
  volume={171 10},
  pages={5498-506}
}
Chemokines play a key role in the recruitment of activated CD4(+) T cells and eosinophils into the lungs in animal models of airway inflammation. Inhibition of inflammation by N-terminally modified chemokines is well-documented in several models but is often reported with limited dose regimens. We have evaluated the effects of doses ranging from 10 ng to 100 micro g of two CC chemokine receptor antagonists, Met-RANTES/CC chemokine ligand 5 (CCL5) and aminooxypentane-RANTES/CCL5, in preventing… CONTINUE READING